ArticleCancers2022

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy.

Elizabeth Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.